Study discovers novel therapeutic targets for Huntington's disease

February 27, 2014

A study led by researchers at Boston University School of Medicine (BUSM) provides novel insight into the impact that genes may have on Huntington's disease (HD). The study, published online in PLOS Genetics, identified specific small segments of RNA (called micro RNA or miRNA) encoded in DNA in the human genome that are highly expressed in HD. Micro RNAs are important because they regulate the expression of genes. The researchers showed that these miRNAs are present in higher quantities in patients with HD and may act as a mitigating factor in the neurologic decline associated with the disease, making them a possible therapeutic target.

HD is an inherited and fatal neurological disorder that is usually diagnosed when a person is between 30 and 50 years old. Huntingtin, the single gene mutation responsible for the disease, was identified in 1993.

The investigators examined 21 autopsy brain samples: 12 with HD and nine without. Genetic sequencing analyses were performed on these brain tissues, including quantifying the amount of all the microRNAs present in the brain and their corresponding gene or messenger RNA (mRNA) counterparts. This information was combined with a genetic study to characterize variations in the HD gene. The researchers also gathered the clinical neurological information on the patients' age when HD symptoms presented and how long the patient survived with the disease.

Based on this analysis, the investigators discovered increased amounts of four miRNAs were expressed in the brains of HD patients and that the amount of miRNA was highly correlated with disease status. An increased amount of miRNA in was correlated with a younger age at disease onset and an earlier age at death of the patients.

"The genes which these miRNAs regulate also had increased levels, indicating that these , indicating that these gene products were likely targeted for storage and for possible future use within the brain cell, rather than for destruction. When we experimentally increased the expression of the microRNAs in model nerve cells designed to replicate the conditions of HD, the cells lived longer, indicating that these miRNAs may promote cell survival," explained lead author Richard Myers, PhD, professor of neurology at BUSM. The authors conclude that these genes may represent new therapeutic targets for HD.

According to the researchers, these miRNA sequences were found to be present in much higher levels in patients with HD (some were undetectable in the cells of normal patients), which would also make them excellent targets as biomarkers for HD expression. "If this miRNA were also found outside of , for example in the blood, it could be used as an inexpensive, non-invasive assessment of the severity of the disease and perhaps for evaluating the effectiveness of treatments in clinical trials for HD. If the amount of miRNA were quantified in an HD patient, the amount could provide insight into the likely age of disease onset or life expectancy of the patient which current genetic testing in HD does not provide," added Myers.

Explore further: Study identifies pathology of Huntington's disease

Related Stories

Study identifies pathology of Huntington's disease

October 17, 2012
A study led by researchers at Boston University School of Medicine (BUSM) provides novel insight into the impact that Huntington's disease has on the brain. The findings, published online in Neurology, pinpoint areas of the ...

Immune cell migration is impeded in Huntington's disease

November 19, 2012
Huntington disease (HD) is an incurable neurodegenerative disease caused by a mutation in the huntingtin gene (htt). Though most of the symptoms of HD are neurological, the mutant HTT protein is expressed in non-neural cells ...

Predicting outcome for high-dose IL-2 therapy in cancer patients

December 2, 2013
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going ...

Study puts Huntington's disease trials on TRACK

May 21, 2013
(Medical Xpress)—A three-year multinational study has tracked and detailed the progression of Huntington's disease (HD), predicting clinical decline in people carrying the HD gene more than 10 years before the expected ...

Huntington disease prevention trial shows creatine safe, suggests slowing of progression

February 7, 2014
The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease (HD) reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. ...

Recommended for you

Touching helps build the sexual brain

September 21, 2017
Hormones or sexual experience? Which of these is crucial for the onset of puberty? It seems that when rats are touched on their genitals, their brain changes and puberty accelerates. In a new study publishing September 21 ...

Gene immunotherapy protects against multiple sclerosis in mice

September 21, 2017
A potent and long-lasting gene immunotherapy approach prevents and reverses symptoms of multiple sclerosis in mice, according to a study published September 21st in the journal Molecular Therapy. Multiple sclerosis is an ...

Neuron types in brain are defined by gene activity shaping their communication patterns

September 21, 2017
In a major step forward in research, scientists at Cold Spring Harbor Laboratory (CSHL) today publish in Cell a discovery about the molecular-genetic basis of neuronal cell types. Neurons are the basic building blocks that ...

Highly precise wiring in the cerebral cortex

September 21, 2017
Our brains house extremely complex neuronal circuits whose detailed structures are still largely unknown. This is especially true for the cerebral cortex of mammals, where, among other things, vision, thoughts or spatial ...

Your neurons register familiar faces, whether you notice them or not

September 21, 2017
When people see an image of a person they recognize—the famous tennis player Roger Federer or actress Halle Berry, for instance—particular cells light up in the brain. Now, researchers reporting in Current Biology on ...

Faulty cell signaling derails cerebral cortex development, could it lead to autism?

September 20, 2017
As the embryonic brain develops, an incredibly complex cascade of cellular events occur, starting with progenitors - the originating cells that generate neurons and spur proper cortex development. If this cascade malfunctions ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.